August 2023 - CBDWire

ThursdayAug 31, 2023 10:30 am

Alternative Products Expo: Innovation and Sustainability

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees. Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for…

ThursdayAug 24, 2023 9:45 am

Alternative Products Expo: Pioneering the Counterculture Industry

Counterculture retail professionals, business executives, researchers, and industry leaders, are invited to attend Alternative Products Expo to be held in Las Vegas from September 14-16, 2023. Dedicated to promoting creativity, the much-awaited event will be focused on eco-friendly solutions and alternative products. The Expo is set to engage audiences with a wide range of unique and sustainable products that signify the latest trends and technological advancements. The Expo aims to empower participants to make informed buying decisions while contributing to a progressive, more sustainable future. By showcasing a wide range of ethically sourced and environmentally friendly alternatives, the Expo is…

TuesdayAug 22, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design It also affirmed Lexaria's product superiority while also showing DehydraTECH’s potential Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time…

MondayAug 21, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology

Lexaria's human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company's DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects A new patent has been granted to Lexaria and is strategically important to the company's oral nicotine sector research and development efforts Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results and the intent to develop a human clinical study Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that…

ThursdayAug 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1 The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with its DehydraTECH(TM) technology Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control…

TuesdayAug 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine” The company described the new patent as “strategically important” The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world’s leading oral nicotine markets This patent could also lead to additional subsequent patents from within this family Lexaria’s DehydraTECH-nicotine formulation is patent granted for oral nicotine delivery in the US, Canada, and Australia When Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

FridayAug 04, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Incorporates New Subsidiary, Lexaria Nutraceutical Corp., for Non-Pharmaceutical, Non-Nicotine, and Non-Cannabis DehydraTECH(TM) Formulations

Lexaria Nutraceutical Corp. will keep Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets, excluding pharmaceutical, nicotine, and cannabis molecules Lexaria Pharmaceutical Corp.’s licensing was amended so as to solely focus on pharmaceutical formulations excluding nicotine Lexaria announced in early May that its nicotine trial, NIC-H22-1, had completed dosing with results expected in the near future NIC-H22-1 is anticipated to intercede the oral nicotine pouch market, which had a global value of $2.33 billion in 2020, and is expected to grow to $21.84 billion by 2027 Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug…

News and publishing service for CBD related companies

Contact us: 303.498.7722

Month: August 2023